Foreword

Sandy Costa was president and COO of the S&P 500Quintiles during their six-year growth from $90 million to$1.6 billion and from 1,000 to 20,000 employees. There weremany successful acquisitions in that time—a feat in and ofitself—but more than 60 percent of that growth was organic.Prior to joining Quintiles, Mr. Costa held the positions ofGeneral Counsel and Senior Vice President Administrationwith Glaxo, Inc., U.S. Area Counsel with Merrell DowPharmaceuticals, and Food & Drug Counsel with NorwichEaton Pharmaceuticals. In addition to Chairman of the Boardat Labopharm, Mr. Costa currently serves as directorof Cytokinetics and Biovest I. Mr. Costa is an adjunctprofessor in the clinical research program at theCampbell University School ...

Get Growth or Bust now with the O’Reilly learning platform.

O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.